{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"4.2","value":"2.7"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"3.0","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the PDL-1 Positive Analysis Set","dispersionType":"95% Confidence Interval","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The PD-L1 positive population is defined as a visually-estimated combined positive score (vCPS) ≥10%","reportingStatus":"POSTED","timeFrame":"Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)","title":"Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set","type":"SECONDARY","unitOfMeasure":"Months"}